| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly is experiencing significant momentum in the development of new obesity drugs, particularly with the high expectations surrounding their upcoming weight-loss treatment. Their commitment to expanding manufacturing capacity underscores a proactive approach to meet anticipated market demand. Innovations in their product pipeline, especially targeting obesity and diabetes, highlight strong potential for revenue growth. Overall, the combination of strong R&D and manufacturing investment positions the company favorably within the pharmaceutical industry. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.7, and the negative at -0.2 on 2025-11-06. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.9) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | 0%(0%) | 0 | 0% | 0.5 | 3.9 | 0.3 | |||||||
| 2025-11-05 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | -1 | |||||||
| 2025-11-04 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | 5.3 | |||||||
| 2025-11-03 | 0%(0.1%) | 0 | 0% | 0.6 | 4.8 | -1 | |||||||
| 2025-11-02 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | -1 | |||||||
| 2025-11-01 | 0%(0.1%) | 0 | 0% | 0.6 | 4.6 | -1 | |||||||
| 2025-10-31 | 0%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.5 | |||||||
| 2025-10-30 | 1%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.8 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | 7 | |||||||
| 2025-10-28 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | 5.5 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-06 22:48:26 The deal suggests a potential shift in regulatory practices affecting drug prices and accessibility for Medicare and Medicaid beneficiaries. |
| 2025-11-06 22:48:26 The partnership between the Trump administration and major drug manufacturers Eli Lilly and Novo Nordisk highlights collaboration in the healthcare sector. |
| 2025-11-06 22:48:26 The article discusses a pricing deal aimed at reducing costs for certain weight-loss drugs, indicating a positive sentiment towards cost reduction in pharmaceuticals. |
| 2025-11-06 17:02:18 The stock performance of Eli Lilly and its competitors has been positively affected by news of drug pricing agreements and FDA trial results. |
| 2025-11-06 17:02:18 Eli Lilly's advancements in experimental obesity medications demonstrate ongoing innovation in the healthcare sector aimed at tackling obesity. |
| 2025-11-06 17:02:18 Recent changes in Eli Lilly's executive leadership aim to drive growth and enhance their drug pipeline, influencing the company’s operational direction. |
| 2025-11-06 17:02:18 The announcements regarding agreements to lower the prices of weight loss drugs highlight cost concerns and the impact on patient access. |
| 2025-11-06 17:02:18 Eli Lilly has engaged in partnerships with the U.S. government to enhance access to obesity medications, especially for Medicare beneficiaries. |
| 2025-11-06 15:49:45 Despite positive earnings results, Ralph Lauren's stock is under pressure, indicating mixed market reactions to company performance. |
| 2025-11-06 15:49:45 The collaboration between Eli Lilly, Novo Nordisk, and the Trump administration could be seen as an effort towards more accessible medication prices. |
| 2025-11-06 15:49:45 The decrease in flight traffic announced by the FAA has led to a negative impact on airline stock performance. |
| 2025-11-06 15:49:45 The decision by Eli Lilly and Novo Nordisk to lower the cost of GLP-1 medications reflects a positive trend towards reducing healthcare costs for consumers. |